Abstract
The effect of bladder surgery on the pharmacokinetics of tobramycin in hospitalized patients was studied. Fourteen patients with vesical neoplasia undergoing urinary tract surgery were given tobramycin in a dose of 2 mg/kg of body weight. Each patient received the dose at the induction of anesthesia, about 1 h before surgical incision. For seven patients, the drug was also administered 3 weeks later when nutritional conditions were normal. The pharmacokinetic parameters were determined by a two-compartment open model. Except for renal clearance, no significant difference appeared between pharmacokinetic parameters determined from serum data during peri- and postoperative periods. During this work, tobramycin excretion in urine was studied. Twenty-four hours after drug administration, the mean urine tobramycin levels were 25.5 +/- 9.06 and 41.6 +/- 21.5 micrograms/ml after peri- and postoperative administration, respectively; these values were higher than the MICs for most urinary tract pathogens. Seventy-two hours after perioperative administration, the mean value was still elevated (3.54 micrograms/ml), but 72 h after postoperative administration, the urinary tobramycin concentration was not detectable. The percentages of tobramycin recovered unchanged in urine were 54 and 79% after peri- and postoperative administration, respectively. When tobramycin was administered during surgery, a long terminal log-linear phase, with a mean half-life of 25.6 h, was detected. The ratio of renal clearance to total body clearance was 0.52 and 0.79 after peri- and postoperative administration, respectively.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adelman M., Evans E., Schentag J. J. Two-compartment comparison of gentamicin and tobramycin in normal volunteers. Antimicrob Agents Chemother. 1982 Nov;22(5):800–804. doi: 10.1128/aac.22.5.800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Botto H., Camey M. Antibiothérapie prophylactique en urologie. Compte rendu de la table ronde du 80e Congrès de l'Association Française d'Urologie (AFU), 1986. Ann Urol (Paris) 1987;21(6):443–449. [PubMed] [Google Scholar]
- Charton M., Vallancien G., Veillon B., Brisset J. M. Antibiotic prophylaxis of urinary tract infection after transurethral resection of the prostate: a randomized study. J Urol. 1987 Jul;138(1):87–89. doi: 10.1016/s0022-5347(17)43000-x. [DOI] [PubMed] [Google Scholar]
- Dettli L. C. Drug dosage in patients with renal disease. Clin Pharmacol Ther. 1974 Jul;16(1):274–280. doi: 10.1002/cpt1974161part2274. [DOI] [PubMed] [Google Scholar]
- Dickson C. J., Schwartzman M. S., Bertino J. S., Jr Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther. 1986 Mar;39(3):325–328. doi: 10.1038/clpt.1986.47. [DOI] [PubMed] [Google Scholar]
- Kloth D. D., Tegtmeier B. R., Kong C., Akahoshi M. P., Leach S. H., Beatty J. D., Zaia J. A. Altered gentamicin pharmacokinetics during the perioperative period. Clin Pharm. 1985 Mar-Apr;4(2):182–185. [PubMed] [Google Scholar]
- Landes R. R. Single daily doses of tobramycin in therapy of urinary tract infections. J Infect Dis. 1976 Aug;134 (Suppl):S142–S145. doi: 10.1093/infdis/134.supplement_1.s142. [DOI] [PubMed] [Google Scholar]
- Péchère J. C., Dugal R. Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients. J Infect Dis. 1976 Aug;134 (Suppl):S118–S124. doi: 10.1093/infdis/134.supplement_1.s118. [DOI] [PubMed] [Google Scholar]
- Schentag J. J., Jusko W. J. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther. 1977 Sep;22(3):364–370. doi: 10.1002/cpt1977223364. [DOI] [PubMed] [Google Scholar]
- Schentag J. J., Lasezkay G., Cumbo T. J., Plaut M. E., Jusko W. J. Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother. 1978 Apr;13(4):649–656. doi: 10.1128/aac.13.4.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Taburet A. M., Steimer J. L., Doucet D., Singlas E. Le temps de présence moyen dans l'organisme. Un nouveau paramètre pharmacocinétique?. Therapie. 1986 Jan-Feb;41(1):1–10. [PubMed] [Google Scholar]
- Wilson J. A., Hackett R. L., Finlayson B. Tobramycin and renal ischemia. Urology. 1986 Nov;28(5):409–412. doi: 10.1016/0090-4295(86)90075-0. [DOI] [PubMed] [Google Scholar]
- Wilson N. I., Lewi H. J. Survey of antibiotic prophylaxis in British urological practice. Br J Urol. 1985 Aug;57(4):478–482. doi: 10.1111/j.1464-410x.1985.tb06316.x. [DOI] [PubMed] [Google Scholar]
- Winslade N. E., Adelman M. H., Evans E. J., Schentag J. J. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers. Antimicrob Agents Chemother. 1987 Apr;31(4):605–609. doi: 10.1128/aac.31.4.605. [DOI] [PMC free article] [PubMed] [Google Scholar]